Michael Vu, DO

Out with the old and in with the new. Excited for the next 3 years of Cardiology Fellowship! A lot of growth and learning ahead *insert motivational David Goggins quote* Please share any/all tips on how to survive fellowship! #MedTwitter

"TOGETHER WE ARE AMERICA" Bad Bunny held out a football with this message written on it at the end of his Super Bowl halftime show 👏

MASSIVE problem with AHA PREVENT risk score in real-world data from Kaiser-Permanente Among young Black Americans, the PREVENT underestimates risk by ~46%! This leads to significant under-treatment of Black folks with life-saving cholesterol/BP meds 🔗in reply

Added bonus: I got to open my Match email in Puerto Natales…right before hiking Patagonia!

It’s a final match! I am blessed to have matched Advanced Heart Failure & Transplant at @NMCardioVasc @WeAreNUHeart. This is could not have been possible without the endless support and guidance from my mentors, colleagues, family, and wife. Excited for a 🥶 year!

Diagnosing transthyretin cardiac #amyloidosis: #whyCMR ECV accurately differentiates disease with negative or equivocal PYP from biopsy-negative phenotypic controls. jacc.org/doi/10.1016/j.… #JACCIMG #ATTR

#ACCFIT #MedEd #Cardiology #AHFTX

Certified & official! It’s surreal that this is the last Match I participate in. Despite what the statistics may suggest, I am more excited than ever to be an Advanced Heart Failure & Transplant Cardiologist. It was inspiring to connect with so many passionate about this field ❤️

#CardiovascularCaseSeries: In this novel format, a case is presented in stages to expert clinician, @JLGrodin, who responds to information and shares their reasoning with the reader. This case features a patient with concomitant ATTR and... ahajrnls.org/3LkkdRB @LeonardChiuMD

Bad news for enthusiasts of left atrial appendage closure from #AHA25. CLOSURE-AF is not yet published, but reports from New Orleans indicate inferiority compared with best medical care (the trial was designed for non-inferiority, making this the most unexpected and unfavorable scenario). In 888 patients with atrial fibrillation considered at high risk for stroke and bleeding, a composite endpoint of stroke, systemic embolism, cardiovascular or unexplained death, and major bleeding occurred in 16.83% of patients who underwent left atrial appendage closure and 13.27% of those receiving best medical care (whose exact definition remains unclear — we’ll hopefully find out once the paper is available). These appear to be patients in whom the appendage is perhaps closed somewhat lightly — the rationale often being “so they won’t need lifelong anticoagulation.” Well, lifelong benefit remains to be seen, but after a median follow-up of 3 years, the risk of events was 28% higher with appendage closure, with a 95% confidence interval for the hazard ratio indicating a potential 1 to 62% increase in risk. In short, the results are not definitely encouraging, and much remains to be understood. Which events increased? Likely ischemic ones. And further — was it appropriate for the trial to combine ischemic and bleeding events, along with cardiovascular death, into a single non-inferiority endpoint? Probably not, yet the findings have disrupted expectations and made the discussion quite compelling nonetheless. Finally, could the expected long-term reduction in events (beyond 3 years, potentially lifelong) eventually offset the initial, possibly procedural and hemorrhagic, risks — shifting the balance back in favor of closure for patients with longer life expectancy and prolonged exposure to anticoagulation? Hard to say without full data. And in any case, this is only one trial; at least three others are ongoing in high bleeding-risk populations (STROKECLOSE, CLEARANCE, and LAA-KIDNEY). Let’s also recall that somewhat more favorable data have been seen in anticoagulation-eligible populations, but at this stage it seems appropriate to pause and reflect. If you’d like to reflect with us, join the @escardio webinar on Monday, where I’ll also be participating — it feels perfectly timed. esc365.escardio.org/event/2097

In this CSWG analysis, patients supported with Impella 5.5 beyond the FDA-approved duration of 14 days had high rates of favorable outcomes, especially as bridge to #heart replacement therapies. @manreetkanwar @NirUrielMD @NavinKapur4 🫀 🔗: jhltonline.org/article/S1053-…

Congratulations to Blen Daniel, FNP-BC, MSN, ARPN of @bswhealth for being awarded the HFSA Nursing New Investigator Research Category Award for the research field for their incredible early protocolized team based identification of candidates for possible advanced heart failure. Research is critical to the future of #HeartFailure care. ❤️📈 We are proud to honor these nursing investigators! 🙌 #HFSA2025

📰 Increasing VA-ECMO Flow Rarely Raises PCWP in Patients With Cardiogenic Shock Read the journal scan for more ➡️ bit.ly/428CO8H #JACC #HeartFailure

Beta-blockers in patients with heart failure with reduced ejection fraction and concomitant chronic obstructive pulmonary disease: Cardiovascular and respiratory outcomes In patients with HFrEF and COPD, beta-blocker use was associated with lower risk of cardiovascular death/total HHF, without evidence of safety concerns for COPD exacerbations. @SJGreene_md @gcfmd @DrMarthaGulati @hvanspall @dranulala @AndrewJSauer @ankeetbhatt @BiykemB @hfcollaboratory @HFSA @GMCRosano @HFA_President onlinelibrary.wiley.com/doi/full/10.10…

What a milestone! Board certified in Adult Echocardiography 🥳 thankful for the amazing echo and imaging attendings at @HeartPlano. @ASE360 @NBE_96 #ACCFIT

What a milestone! Board certified in Adult Echocardiography! Thankful to the echo and imaging attendings at @HeartPlano for the years of teaching. @ASE360

Day 1 of Dallas PCI is almost here! Dr. Widmer, Dr. Ryan & Dr. Ogugwa lead our live microvascular disease case with a stellar team of doctors alongside them. Stay tuned for more previews as we gear up for the big event! Register now: dallaspci.com #DallasPCI #FACET

Join us this Saturday!

Presented at #ESCCongress: In patients with chronic coronary syndrome taking oral anticoagulants, adding aspirin led to higher risks of cardiovascular events, major bleeding, and death from any cause than anticoagulation alone. Full AQUATIC trial: nej.md/45AU4Wp @escardio

#ESC2025 #SimPub: CASTLE-HTx 3-year outcomes: In patients with end-stage heart failure, AF ablation sustained survival & reduced the need for surgical HF therapies over 36 months, with fewer deaths & LVAD/HTx procedures than medical therapy alone. ahajournals.org/doi/full/10.11…

Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: @NEJM 🥸 Mavacamten is a no go for non-obstructive HOCM 😱Summary 👇👇👇